Recruiting

Testing a New Skin Treatment for Moderate to Severe Eczema

Plain-English translation of NCT07230860 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This clinical trial is testing a new medication called to see if it can help people with moderate to severe atopic dermatitis (eczema) feel better and reduce their symptoms. Researchers want to find the right dose of this medication and compare it to placebo (an inactive treatment) to understand how well and safely it works.

Many people with moderate to severe eczema don't respond well enough to existing treatments like creams and ointments, or they can't tolerate systemic medications. This trial is exploring whether this medication offers a better option for people who need more help managing their condition.

Do you qualify?

You likely qualify if…

you have been diagnosed with atopic dermatitis (eczema) that has lasted at least one year
your eczema is moderate to severe, affecting at least 10% of your body
your eczema has not responded adequately to topical treatments (creams) or systemic medications in the past year
you are otherwise healthy and willing to visit the clinic multiple times over six months
you are willing to sign a consent form showing you understand the study and agree to participate

You likely don't qualify if…

you have a history of substance abuse or alcohol abuse in the past year
you have a weakened immune system or a history of serious infections
you have ever received JNJ-95597528 before
you have a known allergy to this medication or similar biologic medications
you have abnormal results on screening tests that would affect your safety in the study

What participation looks like

If you join this study, you will be randomly assigned to receive either the medication at different doses or a placebo (inactive treatment). You will receive injections at specific visits over a 24-week period—at weeks 0, 12, and 24 (with some groups getting doses at week 2 as well). You'll attend several clinic visits for check-ups, blood tests, and skin assessments to see how well the medication is working and to monitor for any side effects.

AI-generated summary from trial data · Jun 3, 2026 · Not medical advice

Trial locations(56 sites)

United States

First OC Dermatology, Fountain Valley, California

Southern California Dermatology, Santa Ana, California

Driven Research LLC, Coral Gables, Florida

Arlington Dermatology, Rolling Meadows, Illinois

Dawes Fretzin Clinical Research Group, Indianapolis, Indiana